Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study (Q34652628)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

0 references

metastatic melanoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Caroline Robert

1

object named as

Caroline Robert

0 references

object named as

Ana Arance

7

0 references

object named as

Paul Lorigan

4

0 references

Dirk Schadendorf

9

object named as

Dirk Schadendorf

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Reinhard Dummer

2

object named as

Reinhard Dummer

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

Ralf Gutzmer

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Kevin B Kim

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Marta Nyakas

6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Gabriella Liszkay

8

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Mireille Cantarini

10

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Stuart Spencer

11

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Mark R Middleton

12

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

publication date

2 June 2013

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

733-740

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved survival with MEK inhibition in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of duration of response in oncology trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance to BRAF-targeted therapy in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970237-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70237-7

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34652628&oldid=1936896001"